UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

November 16, 2016

Date of Report (Date of earliest event reported)

 

ABBOTT LABORATORIES

(Exact name of registrant as specified in its charter)

 

Illinois

 

1-2189

 

36-0698440

(State or other jurisdiction
of incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)

 

(Registrant’s telephone number, including area code): (224) 667-6100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 5.02                                           Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

As previously reported, Abbott has Agreements Regarding Change in Control (“Agreements”) with its named executive officers, other than Miles D. White, Abbott’s Chairman of the Board and Chief Executive Officer, who is not party to an Agreement Regarding Change in Control.

 

The Agreements provide that if Abbott gives notification of extension before the Expiration Date (December 31, 2016), the Agreement’s term shall continue through the second anniversary of the Expiration Date.

 

On November 16, 2016, Abbott notified the named executive officers who are party to the Agreements that the term of the Agreements was extended through December 31, 2018.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ABBOTT LABORATORIES

 

 

 

 

Date:  November 16, 2016

By:

/s/ Brian B. Yoor

 

 

Brian B. Yoor

 

 

Senior Vice President, Finance

 

 

and Chief Financial Officer

 

3